Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Asthma Telemedicine Should Reduce Asthma Deaths: Teijin Seminar
February 19, 2001
- Non-compliance with GCP Found in 1,529 Cases in 3-year Survey
February 12, 2001
- Fukujin Ties Up with Inagaki Yakuhin
February 12, 2001
- OTC NEWS IN BRIEF
February 12, 2001
- BUSINESS NEWS IN BRIEF -1-
February 12, 2001
- MEDICAL DEVICE NEWS IN BRIEF
February 12, 2001
- BUSINESS NEWS IN BRIEF -2-
February 12, 2001
- DIAGNOSIS NEWS IN BRIEF
February 12, 2001
- Aiming to Rank 20th within This Year: Mr Payne of Pharmacia
February 12, 2001
- ABBREVIATION OF THE WEEK
February 12, 2001
- Korosho Calls For National Debates on Healthcare Reform
February 12, 2001
- AstraZeneca Aiming at Entering Top 10 by End of 2005: Mr Angelici
February 12, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -1-
February 12, 2001
- Rush of New Drug Launches from Foreign Companies Continues
February 12, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -2-
February 12, 2001
- Pharmacists Should Serve as Risk Managers: SJP Seminar
February 12, 2001
- Taisho Licenses in Antiobesity Agents from Arena
February 12, 2001
- WORLD NEWS IN BRIEF
February 12, 2001
- REGULATORY NEWS IN BRIEF
February 12, 2001
- Asahi Chemical, Janssen-Kyowa to Make Utmost Efforts to Expand Japan's 1st SNRI Market
February 12, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…